ASCO GU 2018Renal cancerBEST ABSTRACTS

Dr. Felipe MoraesOncologista ClinicoBP – A Beneficência Portuguesa de SP

>100 abstracts…

What we need to know?

Sumary

Biomakers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Sumary

Biomakers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Paguei uma nota e... Nada!

Sorry… nothing amazing

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

sumary

Biomakers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Surgery

Dados retrospectivos 2003-201524145 pacientesSO aberta x laparoscopica x robotica

Menos tempo de UTI e transfusao com tecnica minimante invasivasLaparoscopia com melhor relacao custo-beneficio

Reducao de 30% em complicacoes nos primeiros 90 dias.

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Surgery

10477 pacientes idososObservacao x Resseccao ou ablacaoRetrospectivos

Aparente beneficio em OS. Medida em 05 e 10 anosAblacao: 97% - 96%Observacao: 83% - 74%Cirurgia: 96% - 94%

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Surgery

15068 pacientes com dados retrospectivosNCBDUpfront x TT first

OS: 16.5meses x 9 mesesHR 0.62 (95%CI 0.61 x 0.64)

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Surgery

353 pacientes, estudo retrospectivo multicentrico.OS CN: 16.3meses (95%CI: 13.1-19.2) X No CN: 8.6meses (95%CI: 6.1-12.2)

HR: 0,62 (0.45-0.85)

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

sumary

Biomakers…

Surgery

Adjuvant setting

Metastatic setting

News drugs

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Adjuvant setting

771 pacientesEstudo multicentricoIdentificou fatores de risco de recorrencia

Diametro > 7cmNecroseGN 4Componente sarcomatoide

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Adjuvant therapy

Estudo em andamento722 pacientes T2 maior ou igual ou LFNRFSOS

RANDOMIZADOS

NIVO 2 doses -> SO -> q2w 3m + q4w 6m.

Observacao

COMMING SOON

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Adjuvant therapy

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Adjuvant therapy

ASSURE S-TRAC PROTECT

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Sumary

Biomakers…

Surgery

Adjuvant setting

Metastatic setting

News drugs

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

First line

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

EUROPEAN UROLOGY 73 ( 2018 ) 311– 315

Tratamento do Câncer de Rim ECIV

First Line

915 pacientesPacientes virgens tratamentoEstratificados por PD-L1 (1%)PFS em PDL1+ (40%)OS

RANDOMIZADOS

Atezo 1200mg + Bev 15mg/kg q3wN = 454

Sunitibe 50mg PO 4w on/2w offN = 461

OS: dados imaturos

PFS – HRPD-L1+: 0.74 (95%CI 0.57-0.96)ITT: 0.83 (95%CI 0.7-0.97)

Toxicidades G3 ou G412% Atezo + Beva8% Sutent

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

First Line

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

First Line – phase I

Estudo Fase Ib em andamento52 pacientes virgens tto1º: DLT2º: Security, ORR, PFS, OS

Axitinibe 5mg twice a day +Pembro 2mg/mg q3w

End-Point- 3 DLT

Toxicities (G3)- Hipertensao: 23%- Diarreia: 10%- Fadiga: 10%

ORR- 73.1 %

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

First Line… loading

Baseado na aprovacao da associacao de cabo+everolimus em segunda linha.

RANDOMIZADOS

LEN 18mg/d + EV 8mg/d

Sunitibe 50mg PO 4w on/2w off

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

Len 20mg/d + Pembro 200mg q3w

Sumary

Biomakers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

New drugs27 pacientes previamente tratados.

1PR / 21SD/ PFS: 7.1meses. G3: Fadiga:11%/ Hiperglicemia:7%/ Neutropenia:7%Inibidor de glutaminase

Sitravatinibe TKI em associacao com imuno... Em segunda linha...

Tivozanibe18 pacientes.

Hipertensao, anemia e mucosite. TKI mais seletivo. Terapia tripla em primeira linha?

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

New drugs

Terapia celular9 pacientes tratados. Preparo de celulas dentricias para CAIX targetApenas 01 resposta estavel. Mais importante pela sua factibilidade.

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

New drugs9 pacientes tratados. Molecula de down-regulation de oncogenes

Aparentemente segura em associacao com axitinibeSelenio

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

New drugs9 pacientes tratados. Molecula de down-regulation de oncogenes

Aparentemente segura em associacao com axitinibePexa-vec

ASCO 2018 – Meeting Library/ Urotoday.com database/ TBCC Library Archives - Calgary University Archives

In the MET+ patients (n=4), 2 achieved a partial response and 1 had stable disease (ORR 50%; 95% CI: 6.8-93.7%). One year overall survival was 75.0%

CRIZO

Melhores resultados que os controles historicos com uso de QT, poucos

pacientes

Thanks…Contact: felipe73.moraes@gmail.com

BP Mirante - Oncology Center.